PureTech reports positive data from cancer drug trial

April 22, 2026 7:00 AM

PureTech Health plc (NASDAQ: PRTC, LSE: PRTC) announced positive results from a Phase 1b clinical trial of LYT-200, an anti-galectin-9 ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

No results found